An extended-release oral tablet formulation of ketamine has shown promise for treatment-resistant depression (TRD) results of a phase 2 proof-of-concept study suggest. In the trial, twice weekly dosing of extended-release ketamine led to statistically significant and clinically meaningful improvement in depressive symptoms.  Overall tolerability was “excellent,” researchers reported, and common side effects commonly associated with intravenous or intranasal ketamine […]